Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-03-15
2011-10-04
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000, C514S564000
Reexamination Certificate
active
08030294
ABSTRACT:
The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
REFERENCES:
patent: 3873698 (1975-03-01), Penn
patent: 4027017 (1977-05-01), Hata et al.
patent: 4048316 (1977-09-01), Penn
patent: 4115576 (1978-09-01), Penn
patent: 4346084 (1982-08-01), Growdon et al.
patent: 4386077 (1983-05-01), Borgo
patent: 4569929 (1986-02-01), Growdon et al.
patent: 4704361 (1987-11-01), Miccoli et al.
patent: 4764603 (1988-08-01), Zappia et al.
patent: 4960759 (1990-10-01), De Luca et al.
patent: 4999382 (1991-03-01), Wurtman et al.
patent: 5179126 (1993-01-01), Wurtman et al.
patent: 5278176 (1994-01-01), Lin
patent: 5409946 (1995-04-01), Garvey et al.
patent: 5472958 (1995-12-01), Gunn, Jr. et al.
patent: 5635486 (1997-06-01), Yamamoto et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5888532 (1999-03-01), Pritsos et al.
patent: 5919789 (1999-07-01), Dyke et al.
patent: 5958896 (1999-09-01), Renshaw et al.
patent: 5977174 (1999-11-01), Bradley et al.
patent: 6103703 (2000-08-01), Renshaw et al.
patent: 6132724 (2000-10-01), Blum
patent: 6153653 (2000-11-01), Shashoua
patent: 6258794 (2001-07-01), Renshaw
patent: 6277855 (2001-08-01), Yerxa
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6319953 (2001-11-01), Carlson et al.
patent: 6331568 (2001-12-01), Horrobin
patent: 6410522 (2002-06-01), Ruenberg
patent: 6503951 (2003-01-01), Pischel et al.
patent: 6541043 (2003-04-01), Lang
patent: 6608064 (2003-08-01), McLean et al.
patent: 6624195 (2003-09-01), Horrobin
patent: 6696495 (2004-02-01), Mueller
patent: 6706764 (2004-03-01), Kaddurah-Daouk et al.
patent: 6727231 (2004-04-01), Page et al.
patent: 6852870 (2005-02-01), Stoll
patent: 6989376 (2006-01-01), Watkins et al.
patent: 7026301 (2006-04-01), Cardozo et al.
patent: 7053064 (2006-05-01), Lukas
patent: 7601701 (2009-10-01), Lukas
patent: 7737128 (2010-06-01), Renshaw
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: 2002/0182196 (2002-12-01), McCleary
patent: 2003/0100844 (2003-05-01), Miller et al.
patent: 2003/0114415 (2003-06-01), Wurtman et al.
patent: 2003/0220291 (2003-11-01), Renshaw
patent: 2003/0224435 (2003-12-01), Seiwert
patent: 2003/0232827 (2003-12-01), Meltzer et al.
patent: 2004/0102419 (2004-05-01), Kaddurah-Daouk et al.
patent: 2004/0167093 (2004-08-01), Lukas
patent: 2004/0176316 (2004-09-01), Renshaw et al.
patent: 2004/0192732 (2004-09-01), Pratt et al.
patent: 2004/0266659 (2004-12-01), LaBerge
patent: 2005/0113449 (2005-05-01), Renshaw
patent: 2005/0129710 (2005-06-01), Renshaw et al.
patent: 2006/0128671 (2006-06-01), Kaddurah-Daouk et al.
patent: 2008/0132472 (2008-06-01), Renshaw
patent: 2008/0300214 (2008-12-01), Lukas et al.
patent: 2009/0215714 (2009-08-01), Renshaw et al.
patent: 2010/0041620 (2010-02-01), Renshaw et al.
patent: 2010/0041621 (2010-02-01), Renshaw et al.
patent: 2010/0197628 (2010-08-01), Renshaw et al.
patent: 2010/0222296 (2010-09-01), Renshaw et al.
patent: 3400276 (1985-07-01), None
patent: 0 147 185 (1985-07-01), None
patent: 0 188 647 (1986-07-01), None
patent: 0 188647 (1986-07-01), None
patent: 0 218 190 (1987-04-01), None
patent: 0 431 758 (1991-06-01), None
patent: 0 615 750 (1994-09-01), None
patent: 60-252416 (1985-12-01), None
patent: 63-208524 (1988-08-01), None
patent: 2-500372 (1990-02-01), None
patent: 4-18034 (1992-01-01), None
patent: 7-10823 (1995-01-01), None
patent: 08183737 (1996-07-01), None
patent: 2003-517437 (2003-05-01), None
patent: 2003-528133 (2003-09-01), None
patent: 2003332 (1993-11-01), None
patent: 2128653 (1999-04-01), None
patent: WO 89/03837 (1989-05-01), None
patent: WO 93/14076 (1993-07-01), None
patent: WO 99/26620 (1999-06-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 00/11952 (2000-03-01), None
patent: WO 01/28528 (2001-04-01), None
patent: WO 01/44265 (2001-06-01), None
patent: WO 01/72288 (2001-10-01), None
patent: WO 02/45583 (2002-06-01), None
patent: WO 02/088159 (2002-11-01), None
patent: WO 03/082211 (2003-10-01), None
patent: WO 2005/086619 (2005-09-01), None
patent: WO 2005/122767 (2005-12-01), None
Stedman's Medical Dictionary, 27thedition, Lippincott Williams & Wilkins (2000).
Salvadorini et al., “Clinical Evaluation of CDP-Choline (NICHOLIN®): Efficacy as Antidepressant Treatment,”Current Therapeutic Research18:513-520 (1975).
Wurtman et al., “Effect of Oral CDP-Choline on Plasma Choline and Uridine Levels in Humans”,Biochemical Pharmacology, 60:989-992, (2000).
Lukacsko et al., “Modulation of the Vasoconstrictor Response to Adrenergic Stimulation by Nucleosides and Nucleotides,”J. Pharmocol. Exp. Ther. 222:344-349, 1982.
Tornos et al., “Effect of Oral CDP-Choline on Experimental Withdrawal Syndrome,”Arzneim.-Forsh./Drug Res. 33(II):1018-1021, 1983.
Malec at al.,Polish Journal of Pharmacology48:583-588 (1996)—Abstract.
Connolly et al., “Uridine and its Nucleotides: Biological Actions, Therapeutic Potentials,”TiPS20:218-225 (1999).
Tucker et al. “Inhibition by Adenosine Analogs of Opiate Withdrawal Effects,”NIDA Res Monogr. 49:85-91 (1984). (XP001208315).
Arranz et al., “Treatment of Chronic Dyskinesia with CDP-Choline,”Arzneim.-Forsch. 33:1071-1073, 1983.
Baldessarini et al., “Suicide Risk and Treatments for Patients with Bipolar Disorder,”JAMA290:1517-1519, 2003.
Beers et al., “The Merck Manual of Diagnosis and Therapy,” Merck & Co, Inc., 17th Edition, Chapter 189: Mood Disorders, pp. 1539-1543, 1999.
Cansev, “Uridine and Cytidine in the Brain: Their Transport and Utilization,”Brain Res. Rev. 52:389-397, 2006.
IMSDrugNews Database Entry, Accession No. 2003:368, “Triacetyluridine: Repligen Phase Change II, USA (Bipolar Disease),” p. 1, Feb. 3, 2003.
Mealy et al., “RG-2133,”Drugs of the Future29:969, 2004.
McLean Hospital Press Release, “Repligen Announces Initiation of Clinical Trial of Uridine: McLean Hospital Study Will Assess Changes in Brain Chemistry in Bipolar and Major Depression,” pp. 1-2, Jan. 23, 2003.
Saydoff et al., “Oral Uridine Pro-Drug PN401 Decreases Neurodegeneration, Behavioral Impairment, Weight Loss and Mortality in the 3-Nitropropionic Acid Mitochondrial Toxin Model of Huntington's Disease,”Brain Res. 994:44-54, 2003.
U.S. Department of Health and Human Services, “The Health Consequences of Smoking: Nicotine Addiction (a report of the Surgeon General, 1988),” 1988 (643 pages).
Adibhatla et al., “Citicoline Mechanisms and Clinical Efficacy in Cerebral Ischemia,”J. Neurosci. Res. 70:133-139, 2002.
Agnoli et al., “Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCVD),” Proceedings of the International Meeting on Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine, Sorrento, Italy, Jun. 12-14, 1984, pp. 305-315.
gren et al., “Creatinine and Creatine in CSF: Indices of Brain Energy Metabolism in Depression. Short Note,”J. Neural. Transm. 74:55-59, 1988.
Agut et al., “Cytidine(5′)Diphosphocholine Enhances the Ability of Haloperidol to Increase Dopamine Metabolites in the Striatum of the Rat and to Diminish Stereotyped Behavior Induced by Apomorphine,”Neuropharmacology23:1403-1406, 1984.
Alvarado et al., “1H Magnetic Resonance Spectroscopy (MRS) Assessment of the Effects of Eicosapentaenoic-Docosahexaenoic Acids and Choline-Inositol Supplementation on Children with Attention Deficit Hyperactivity Disorder (ADHD),”VITAE Academia Biomédica DigitalJul.-Sep. 2004 N°20 [Available at http://vitae.ucv.ve/?rv=68]. (pp. 1-18).
Alvarez et al., “Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer's Dis
Clark & Elbing LLP
McIntosh, III Traviss C
The McLean Hospital Corporation
LandOfFree
Compounds for the treatment of psychiatric or substance... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of psychiatric or substance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of psychiatric or substance... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262024